KardiaMobile® 6L: Medical-grade ECGs in 30 seconds with QT measurements

Whenever you need heart rate and rhythm information, KardiaMobile 6L helps you get the clarity you need quickly and easily. With wide-ranging use cases from detecting atrial fibrillation to monitoring QT in clinical research and beyond, KardiaMobile 6L is trusted by leading cardiologists, top biopharma companies, large CROs, Fortune 100 employers, and major healthcare systems.

KardiaMobile® 6L

The first FDA-cleared, 6-lead personal ECG device.

Easier for Patients. Insightful for Clinicians.

In just 30 seconds, KardiaMobile 6L provides access to a high-quality, 6-lead ECG without the hassle of wires, patches, or gels – making it easy for patients in the home or the office.

Ideal for capturing a quick ECG at an office visit or for extended remote monitoring, the easy-to-use KardiaMobile 6L provides flexibility to diagnose and treat patients.

Explore our solutions from hospital to home, powered by KardiaMobile 6L

In-office ECG Solution
In office ecg solution desktop 2x

KardiaStation™ App

Designed for clinicians to record and view ECGs efficiently at point-of-care. Triage patients in minutes with a HIPAA-compliant, SOC-2 certified system.

More information for Providers and Biopharma.

Remote Monitoring Solution
Remote monitoring solution desktop 2x

KardiaRx App

Designed for patients and clinical trial participants to record ECGs easily from home. Data are securely and automatically transmitted, enabling timely professional review of rate and rhythm information.

More information for Providers and Biopharma.

Trusted results that help you treat with confidence

The world’s leading cardiologists use KardiaMobile, the most clinically validated personal ECG brand with over 185 clinical publications. Learn how KardiaMobile 6L can help you better treat your patients.

Atrial Fibrillation

AFib Detection You Can 
Count On2

  • 89% pooled sensitivity
  • 99% pooled specificity

Meta-analysis of 14 studies (>8,000 ECGs) evaluating the accuracy of KardiaMobile vs gold standard 12-lead ECG or Holter for AFib detection.

Estimated AFib detection probabilities of KardiaMobile ECG monitoring vs Routine Care over 52 weeks. Shaded area = 95% confidence (P=0.004).

Read More

Accurate AFib Detection3

  • Nearly 4-fold increase in detection over routine care

Randomized controlled trial, REHEARSE-AF, evaluated AFib detection of KardiaMobile vs. routine care in over 1,000 patients with 2x weekly ECGs over 12 months (or if symptomatic).

Accurate afib detection desktop 2x

Estimated AFib detection probabilities of KardiaMobile ECG monitoring vs Routine Care over 52 weeks. Shaded area = 95% confidence (P=0.004).

Read More

QT Monitoring

Confidently prescribe QT-prolonging medication

Streamline QT interval monitoring with an accurate measurement in only 30 seconds for QT-prolonging medications.

  • 250+ medications known to prolong QT intervals4
  • KardiaMobile 6L accurately measures QT intervals5
    • 0.97 Area Under the Curve
    • 80.0% Sensitivity
    • 94.4% Specificity
  • Leverages FDA-cleared algorithm for QT interval measurement
Read More

Post-TAVR Monitoring

Hassle-free for patients

KardiaMoblie 6L was used post-TAVR with consecutive patients to monitor for delayed conduction disease in an elderly population (average age 81.8) for one month.1 Patients were trained on the device and submitted ECGs daily for the 1st week and weekly thereafter.

  • 96.5% successful ECG submission
  • 98.4% of ECGs were of adequate quality for diagnosis & interval measurement
  • Patients were very satisfied with KardiaMobile (4.6 out of 5)
Read More


Demonstrated higher accuracy than single-lead smartwatches6

Study findings suggest that KardiaMobile 6L provides a clinical benefit with higher accuracy compared to single-lead smartwatch devices when reviewed by a cardiologist.

  • KardiaMobile demonstrated better detection of AFib and Sinus Rhythm
  • ~2x more accurate detection of Atrial Flutter
  • Preferred by Cardiologists
Read More

“I am impressed with the quality and simplicity of 6-lead smartphone ECG tracings which will unquestionably sharpen our ability to diagnose heart rhythm and conduction abnormalities.”


Founder and Director Scripps Research Translational Institute, and author of the new book, Deep Medicine

Dr. Topol has no financial relationship with or research support from AliveCor.

Explore how AliveCor's digital health solutions can transform cardiovascular care.


KardiaMobile 6L is not tested or recommended for use with pacemakers and ICDs. KardiaMobile 6L does not check for heart attack.

For compatibility information, visit alivecor.com/compatibility.

1. De Lucia R, et al. Europace (2023) 25, 116-1125.
2. Wong KC et al. Heart. 2020 Aug;106(16):1211-1217.
3. Halcox, JPJ et al. Circulation vol. 136,19 (2017): 1784-1794.
4. Woosley RL, Heise CW, Gallo T, Woosley D and Romero KA, www.CredibleMeds.org, QTdrugs List, September 13, 2023
5. JR et al. Circulation. 2021 Mar 30;143(13):1274-1286.
6. Scholten J et al. Am Heart J. 2022 Nov;253:53-58.